NCT00730782已完成1 期
Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 2
- 主要终点
- Local and systemic reactogenicity
研究概览
简要总结
The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or AS02A or Montanide ISA 720 in healthy adults not previously exposed to the parasite Plasmodium falciparum.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Age > 18 and < 45 years healthy volunteers.
- •General good health based on history and clinical examination.
- •All volunteers have to sign the informed consent form.
- •Negative pregnancy test.
- •Use of adequate contraception for females up to three months after the third injection (D140).
- •Reachable by phone during the whole study period (18 months).
排除标准
- •History of malaria or residence in malaria endemic areas within the past six months.
- •Positive serology for malaria antigen PfAMA-1
- •Previously participated in any malaria vaccine study
- •Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers.
- •Any laboratory abnormalities on screened blood samples beyond the normal range, as defined at UMC St Radboud. Positive HIV, HBV or HCV tests.
- •Volunteers should not be enrolled in any other clinical trial during the whole trial period.
- •Volunteers should not receive chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the three months preceding the screening visit or during the study period.
- •Pregnant or lactating women.
- •Volunteers unable to give written informed consent.
- •Volunteers unable to be closely followed for social, geographic or psychological reasons.
- •Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrollment in the study.
- •Volunteers should not perform exercise four hours before blood draw and should not donate blood for non study-related purposes during the entire duration of the study.
- •Known hypersensitivity to any of the vaccine components (adjuvant or peptide).
- •Volunteers are not allowed to receive any vaccination or gammaglobulin during a period three months prior to the first immunization and up to six months after the 3rd immunization. If a vaccination is necessary during this period, the volunteer will be withdrawn from the study.
- •Volunteers are not allowed to travel to malaria endemic countries during the study period.
结局指标
主要结局
Local and systemic reactogenicity
时间窗: Day 0-14 after each vaccination
次要结局
- Biological Safety(28 days after each vaccination)
- Humoral and Cellular immunogenicity(until 365 days after the first immunisation)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)Healthy VolunteerHVNCT00340574National Institute of Allergy and Infectious Diseases (NIAID)
已完成
1 期
A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum MalariaPlasmodium Falciparum MalariaNCT02044198University of Oxford30
已完成
1 期
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium FalciparumMalariaNCT00487916National Institute of Allergy and Infectious Diseases (NIAID)150
Unknown
1 期
Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])MalariaNCT00431808African Malaria Network Trust40
已完成
1 期
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 AdjuvantMalariaNCT00320658National Institute of Allergy and Infectious Diseases (NIAID)60